The Association for Accessible Medicines (AAM) published a white paper on the impact that ongoing drug shortages have had on the generic and biosimilar industries as well as possible solutions stakeholders can put into action.
A white paper created by the Association for Accessible Medicines (AAM) explaining the myriad of causes that have resulted in mass drug shortages around the world proposed several actions that stakeholders can take to address current challenges and prevent future ones.
“Policymakers, healthcare providers, and manufacturers each play an important role in reducing drug shortages, and all should be cautious of short-term patches that create long-term barriers to robust generic competition and patient access to low-cost medicines,” wrote the authors.
Drug shortages affect about 3% of the branded drug market and between 4% and 6% of the generic market. However, because generic drugs are responsible for more than 90% of small molecule drug prescriptions, external factor influencing supply chain reliability, regulatory delays, or changes in competitive intensity can make producing certain generic products to be financially unsustainable.
The risk of drug shortages is increasing as the long-term sustainability of generic manufacturing faces challenges, including low return on investment because of lowered prices, drug purchasers becoming more concentrated, new generics facing slow adoption, less registered manufacturing sites, and canceled generic launches because of limited commercial opportunities.
The 3 main factors that lead to drug shortages are: (1) market and pricing factors that undermine the sustainability of low-cost generic manufacturing; (2) government policies that compound challenging market dynamics; and (3) regulatory and manufacturing challenges.
The authors broke down each of these factors and their respective causes, including:
Generic drugs are launching at greater discounts from the price of branded drugs, providing short-term savings for patients and payers. However, lower price points for generics can cause companies to discontinue products or close manufacturing facilities, placing a burden on the market.
“Not only might this leave a void that, at best, takes time for other manufacturers to fill, but it may be financially unattractive for another manufacturer to attempt to enter a new market or ramp up production to prevent a shortage. Altogether, this ‘race-to-the-bottom’ calls into question the generic market’s long-term sustainability,” the authors noted.
Additionally, slower adoption for generics makes it more difficult for companies to justify the continued production of medicines that are losing money. On the same note, products that are used on a seasonal or cyclical basic can be affected by unforeseen changes in demand, making it hard for suppliers to ramp up production when another supplier experiences supply disruptions.
The Drug Supply Chain Security Act requires manufacturers to implement interoperable exchange, verification, and tracing for all drug products by November 27, 2023. The ramp up of these policies could cause a spike in drug shortages.
“It is unknown how many generic manufacturers are prepared for this, but some manufacturers will likely not be fully ready for this deadline. And those manufacturers that are fully ready will be asked to supply additional volumes to cover shortfalls when supply may already be constrained,” the authors explained.
The authors suggested several solutions to ensuring a sustainable generic drug market, including:
Other solutions stakeholders could implement sought to increase reserves of critical medicines, improve generic manufacturing capacity, and reduce regulatory and manufacturing challenges, addressing issues regarding:
The authors commented “AAM urges the government to consider the unique aspects that differentiate the brand and generic business models and adopt policies that will reduce drug shortages by improving the long-term sustainability of the generic drug market for patient access and savings.”
Reference
Association for Accessible Medicines. Drug Shortages: Causes & Solutions. AccessibleMeds.org. Published June 22, 2023. Accessed July 24, 2023. https://accessiblemeds.org/sites/default/files/2023-06/AAM_White_Paper_on_Drug_Shortages-06-22-2023.pdf
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.